| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10036449 | HBV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS10050122 | HBV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS30085065 | HIV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20007380 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20007381 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20010779 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20035928 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20057329 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20021555 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
| TVIS20056904 | HPV | ENSG00000196639.7 | protein_coding | HRH1 | No | No | 3269 | P35367 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HRH1 |
|---|---|
| DrugBank ID | DB00768 |
| Drug Name | Olopatadine |
| Target ID | BE0000442 |
| UniProt ID | P35367 |
| Regulation Type | antagonist |
| PubMed IDs | 15942272; 12046981; 8951675; 15646365; 11496828; 20482305; 20406593; 20402382; 11752352 |
| Citations | Tamura T, Masaki S, Ohmori K, Karasawa A: Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology. 2005 Dec;75(1):45-52. Epub 2005 Jun 7.@@Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002 Apr;88(4):379-97.@@Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400.@@Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung. 2004;54(12):809-29.@@Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug]. Nihon Yakurigaku Zasshi. 2001 Jul;118(1):51-8.@@Roland PS, Ryan MW, Wall GM: Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. Expert Opin Pharmacother. 2010 Jun;11(9):1559-67. doi: 10.1517/14656566.2010.485609.@@Kaliner MA, Oppenheimer J, Farrar JR: Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010 Mar-Apr;31(2):112-9. doi: 10.2500/aap.2010.31.3317.@@Roland PS, Marple BF, Wall GM: Olopatadine nasal spray for the treatment of allergic rhinitis. Expert Rev Clin Immunol. 2010 Mar;6(2):197-204.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved |
| Direct Classification | Dibenzoxepines |
| SMILES | CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2 |
| Pathways | Olopatadine H1-Antihistamine Action |
| PharmGKB | PA450698 |
| ChEMBL | CHEMBL1189432 |
